お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
921972

世界の淋病治療市場:成長、動向、および予測

Gonorrhea Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 110 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
世界の淋病治療市場:成長、動向、および予測
出版日: 2020年06月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 110 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートは世界の淋病治療市場について調査しており、市場機会や動向、成長および阻害要因、淋菌感染・治療・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 淋病の増加する負担
    • 全国キャンペーンを通じた政府および民間部門の参加の拡大
  • 市場阻害要因
    • 厳格な規制シナリオ
    • STDクリニックを訪れる患者に関連する社会的スティグマ
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 淋菌感染別
    • 合併症のない淋菌感染
    • 淋菌性関節炎
    • 淋菌性髄膜炎および心内膜炎
  • 治療別
    • モノセラピー
    • デュアルセラピー
  • エンドユーザー別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Allergan, Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Lupin Pharmaceuticals
    • Pfizer Inc.
    • Teligent, Inc.

第7章 市場機会および今後の動向

目次
Product Code: 67485

Gonorrhea is an infection caused by a sexually transmitted bacterium that infects both males and females. The primary factors such as the rising prevalence of gonorrhea, implementation of national screening programs and growing public awareness are propelling the growth of the gonorrhea therapeutics market. According to the Centers for Disease Control and Prevention (CDC), around 700,000 new cases of gonorrhea are detected each year. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) has granted USD 41.6 million over five years to support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea, and chlamydia. Thus, with the growing prevalence of STDs increases patient awareness through national campaigns and growing government initiatives are anticipated to drive market growth.

However, stringent regulatory scenarios and social stigma associated with patients visiting STD clinics are expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Dual Therapy Segment is Expected to Register Good Growth Over the Forecast Period

By Treatment, the market has been segmented into monotherapy and dual therapy. Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity. The dual therapy segment is estimated to dominate the global market, and this trend is expected to continue over the forecast period. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea. WHO recommends dual therapy over monotherapy for people with symptomatic and asymptomatic gonorrhea. Also, monotherapy is no longer a viable option in many settings worldwide. In addition, growing public awareness and a large patient pool also contribute to the growth of the gonorrhea therapeutics market.

North America is Estimated to Lead the Gonorrhea Therapeutics Market

North America is expected to lead the market, owing to high standards of healthcare infrastructure and easy availability of sophisticated technology in this region. As per CDC estimates, in 2018 around 583,405 cases of gonorrhea were reported in the United States. However, Europe and the Asia Pacific are followed next after North America owing to the increasing incidence of gonococcal infection, and the rise in collaboration of domestic and international companies in these regions. For instance, In 2019, Binx health announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval, which is expected to drive the gonorrhea therapeutics market in the forecast period.

Competitive Landscape

The market for gonorrhea therapeutics is consolidated in terms of competition with a presence of few major pharmaceutical companies. Some of the major players in the gonorrhea therapeutics market includes Allergan, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Pfizer Inc, Teligent, Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Gonorrhea
    • 4.2.2 Growing Government and Private Sector Participation Through National Campaigns
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Scenario
    • 4.3.2 Social Stigma Associated With Patients Visiting STD Clinics
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Gonococcal Infection
    • 5.1.1 Uncomplicated Gonococcal Infection
    • 5.1.2 Gonococcal Arthritis
    • 5.1.3 Gonococcal Meningitis and Endocarditis
  • 5.2 By Treatment
    • 5.2.1 Monotherapy
    • 5.2.2 Dual Therapy
  • 5.3 By End User
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan, Inc.
    • 6.1.2 F. Hoffmann-La Roche Ltd
    • 6.1.3 GlaxoSmithKline plc
    • 6.1.4 Lupin Pharmaceuticals
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Teligent, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.